Pneumococcal vaccination and incident hospitalisation for pneumonia in type 2 diabetes: the Fremantle Diabetes Study Phase II

Timothy M.E. Davis; Jane Kauhanen; Wendy A. Davis

doi:10.1111/imj.13569

Pneumococcal vaccination and incident hospitalisation for pneumonia in type 2 diabetes: the Fremantle Diabetes Study Phase II

Timothy M.E. Davis, Jane Kauhanen, Wendy A. Davis

Research output: Contribution to journal › Article › peer-review

7 Citations (Web of Science)

Abstract

Pneumococcal polysaccharide vaccine should be given to patients with diabetes at diagnosis with up to two further 5-yearly doses. In 1465 representative community-based Fremantle Diabetes Study Phase II participants with type 2 diabetes (mean age 66 years, 52% males), 624 (42.6%) self-reported pneumococcal vaccination in the previous 5 years. Vaccination was significantly associated with insulin treatment and cardiovascular pharmacotherapy, suggesting that medical reviews provide the opportunity to address sub-optimal coverage.

Original language	English
Pages (from-to)	1206-1210
Number of pages	5
Journal	Internal Medicine Journal
Volume	47
Issue number	10
DOIs	https://doi.org/10.1111/imj.13569
Publication status	Published - 1 Oct 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/imj.13569

Cite this

@article{5c78d218c96b43009bf0d70150318493,

title = "Pneumococcal vaccination and incident hospitalisation for pneumonia in type 2 diabetes: the Fremantle Diabetes Study Phase II",

abstract = "Pneumococcal polysaccharide vaccine should be given to patients with diabetes at diagnosis with up to two further 5-yearly doses. In 1465 representative community-based Fremantle Diabetes Study Phase II participants with type 2 diabetes (mean age 66 years, 52% males), 624 (42.6%) self-reported pneumococcal vaccination in the previous 5 years. Vaccination was significantly associated with insulin treatment and cardiovascular pharmacotherapy, suggesting that medical reviews provide the opportunity to address sub-optimal coverage.",

keywords = "community-acquired pneumonia, pneumococcal vaccination, type 2 diabetes",

author = "Davis, {Timothy M.E.} and Jane Kauhanen and Davis, {Wendy A.}",

year = "2017",

month = oct,

day = "1",

doi = "10.1111/imj.13569",

language = "English",

volume = "47",

pages = "1206--1210",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "John Wiley & Sons",

number = "10",

}

TY - JOUR

T1 - Pneumococcal vaccination and incident hospitalisation for pneumonia in type 2 diabetes

T2 - the Fremantle Diabetes Study Phase II

AU - Davis, Timothy M.E.

AU - Kauhanen, Jane

AU - Davis, Wendy A.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Pneumococcal polysaccharide vaccine should be given to patients with diabetes at diagnosis with up to two further 5-yearly doses. In 1465 representative community-based Fremantle Diabetes Study Phase II participants with type 2 diabetes (mean age 66 years, 52% males), 624 (42.6%) self-reported pneumococcal vaccination in the previous 5 years. Vaccination was significantly associated with insulin treatment and cardiovascular pharmacotherapy, suggesting that medical reviews provide the opportunity to address sub-optimal coverage.

AB - Pneumococcal polysaccharide vaccine should be given to patients with diabetes at diagnosis with up to two further 5-yearly doses. In 1465 representative community-based Fremantle Diabetes Study Phase II participants with type 2 diabetes (mean age 66 years, 52% males), 624 (42.6%) self-reported pneumococcal vaccination in the previous 5 years. Vaccination was significantly associated with insulin treatment and cardiovascular pharmacotherapy, suggesting that medical reviews provide the opportunity to address sub-optimal coverage.

KW - community-acquired pneumonia

KW - pneumococcal vaccination

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85030705646&partnerID=8YFLogxK

U2 - 10.1111/imj.13569

DO - 10.1111/imj.13569

M3 - Article

C2 - 28994256

AN - SCOPUS:85030705646

SN - 1444-0903

VL - 47

SP - 1206

EP - 1210

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - 10

ER -

Pneumococcal vaccination and incident hospitalisation for pneumonia in type 2 diabetes: the Fremantle Diabetes Study Phase II

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this